Romlusevimab - CISMeF

Preferred Label : Romlusevimab;

NCIt synonyms : Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody BRII-198; Monoclonal Antibody BRII-198; Anti-SARS-CoV-2 S Protein Monoclonal Antibody BRII-198;

NCIt definition : A neutralizing human monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for passive immunization against COVID-19. Upon administration, romlusevimab specifically targets and binds to a specific epitope on the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : SM01RRU9KK;

CAS number : 2509447-08-7;

Molecule name : BRII 198; BRII-198;

NCI Metathesaurus CUI : CL1412583;

Details

Origin ID

C175226;

UMLS CUI

C5578915;

Automatic exact mappings (from CISMeF team)
- BRII-198 [MeSH concept]
Currated CISMeF NLP mapping
- romlusevimab [MeSH concept]
- romlusevimab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- romlusevimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients